CA2382540A1 - High viscosity liquid composition for the delivery of substances - Google Patents
High viscosity liquid composition for the delivery of substances Download PDFInfo
- Publication number
- CA2382540A1 CA2382540A1 CA002382540A CA2382540A CA2382540A1 CA 2382540 A1 CA2382540 A1 CA 2382540A1 CA 002382540 A CA002382540 A CA 002382540A CA 2382540 A CA2382540 A CA 2382540A CA 2382540 A1 CA2382540 A1 CA 2382540A1
- Authority
- CA
- Canada
- Prior art keywords
- delivery
- high viscosity
- solvent
- substances
- viscosity liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0026—Sprayable compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
- Y10T428/2985—Solid-walled microcapsule from synthetic polymer
Abstract
The present invention relates to novel nonpolymeric compounds and compositions that form liquid, high viscosity materials suitable for the delivery of biologically active substances in a controlled fashion, and for use as medical or surgical devices.
The materials can optionally be diluted with a solvent to form a material of lower viscosity, rendering the material easy to administer.
This solvent may be water insoluble or water soluble, where the water soluble solvent rapidly diffuses or migrates away from the material in vivo, leaving a higher viscosity liquid material.
The materials can optionally be diluted with a solvent to form a material of lower viscosity, rendering the material easy to administer.
This solvent may be water insoluble or water soluble, where the water soluble solvent rapidly diffuses or migrates away from the material in vivo, leaving a higher viscosity liquid material.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/385,107 | 1999-08-27 | ||
US09/385,107 US6413536B1 (en) | 1995-06-07 | 1999-08-27 | High viscosity liquid controlled delivery system and medical or surgical device |
PCT/US2000/023270 WO2001015734A2 (en) | 1999-08-27 | 2000-08-24 | High viscosity liquid controlled delivery system and medical or surgical device |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2382540A1 true CA2382540A1 (en) | 2001-03-08 |
CA2382540C CA2382540C (en) | 2009-06-16 |
Family
ID=23520037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002382540A Expired - Fee Related CA2382540C (en) | 1999-08-27 | 2000-08-24 | High viscosity liquid composition for the delivery of substances |
Country Status (9)
Country | Link |
---|---|
US (3) | US6413536B1 (en) |
EP (1) | EP1212092B1 (en) |
JP (2) | JP4276807B2 (en) |
AT (1) | ATE307611T1 (en) |
AU (3) | AU7331900A (en) |
CA (1) | CA2382540C (en) |
DE (1) | DE60023520T2 (en) |
ES (1) | ES2254219T3 (en) |
WO (1) | WO2001015734A2 (en) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833543B2 (en) * | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US6413536B1 (en) * | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
WO2000002564A1 (en) * | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
AUPQ496500A0 (en) * | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
US6992065B2 (en) * | 2000-04-19 | 2006-01-31 | Genentech, Inc. | Sustained release formulations |
US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
US9080146B2 (en) | 2001-01-11 | 2015-07-14 | Celonova Biosciences, Inc. | Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface |
CA2440387A1 (en) * | 2001-03-23 | 2002-10-03 | Durect Corporation | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
US7318931B2 (en) * | 2001-06-21 | 2008-01-15 | Genentech, Inc. | Sustained release formulation |
US20030118658A1 (en) * | 2001-12-21 | 2003-06-26 | Trogolo Jeffrey A. | High aspect ratio encapsulated inorganic antimicrobial additive for controlled release |
US7357949B2 (en) * | 2001-12-21 | 2008-04-15 | Agion Technologies Inc. | Encapsulated inorganic antimicrobial additive for controlled release |
BRPI0307550B8 (en) | 2002-03-12 | 2021-05-25 | Galderma Res & Dev | pharmaceutical composition in topical gel of 0.3% adapalene |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
US8075585B2 (en) * | 2002-08-29 | 2011-12-13 | Stryker Corporation | Device and method for treatment of a vascular defect |
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
US7344505B2 (en) * | 2002-10-15 | 2008-03-18 | Transoma Medical, Inc. | Barriers and methods for pressure measurement catheters |
US7544674B2 (en) | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
US7354574B2 (en) * | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
JP4865330B2 (en) * | 2002-12-13 | 2012-02-01 | デュレクト コーポレーション | Oral drug delivery system |
AU2003301121A1 (en) * | 2002-12-18 | 2004-07-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
KR20050088196A (en) * | 2002-12-19 | 2005-09-02 | 알자 코포레이션 | Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
DE10312346A1 (en) | 2003-03-20 | 2004-09-30 | Bayer Healthcare Ag | Controlled release system |
US7776355B2 (en) * | 2003-07-03 | 2010-08-17 | Medics Pharmaceutical Corporation | Delivery system for topical medications |
US20050025817A1 (en) * | 2003-07-03 | 2005-02-03 | Bhatia Kuljit S. | Delivery system for topical medications |
EP1696868A1 (en) * | 2003-07-18 | 2006-09-06 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
US20070140999A1 (en) * | 2003-07-18 | 2007-06-21 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
US7083802B2 (en) * | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7083803B2 (en) * | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
US20050181018A1 (en) * | 2003-09-19 | 2005-08-18 | Peyman Gholam A. | Ocular drug delivery |
US20060099173A1 (en) * | 2003-10-24 | 2006-05-11 | Nancy Puglia | Topical skin care composition |
EP1711159B1 (en) * | 2003-12-30 | 2013-03-20 | Durect Corporation | Solid implants containing a block copolymer for controlled release of a gnrh compound |
BRPI0418304A (en) * | 2004-01-07 | 2007-05-02 | Trimeris Inc | synthetic peptide, use thereof, pharmaceutical composition, nucleotide sequence, and methods for inhibiting the transmission of hiv to a cell, for inhibiting fusion of hiv, and for treating an HIV-infected individual |
JP2005220333A (en) * | 2004-02-03 | 2005-08-18 | Bmg Inc | Biologically decomposable and absorbable polymer and method for producing the same |
US20050192264A1 (en) * | 2004-02-04 | 2005-09-01 | Penfold Philip L. | Slow release steroid composition |
US8048101B2 (en) | 2004-02-25 | 2011-11-01 | Femasys Inc. | Methods and devices for conduit occlusion |
US8048086B2 (en) | 2004-02-25 | 2011-11-01 | Femasys Inc. | Methods and devices for conduit occlusion |
US9238127B2 (en) | 2004-02-25 | 2016-01-19 | Femasys Inc. | Methods and devices for delivering to conduit |
US8052669B2 (en) | 2004-02-25 | 2011-11-08 | Femasys Inc. | Methods and devices for delivery of compositions to conduits |
US20050256081A1 (en) * | 2004-02-26 | 2005-11-17 | Peyman Gholam A | Tetracycline derivatives for the treatment of ocular pathologies |
US20050192257A1 (en) * | 2004-02-26 | 2005-09-01 | Peyman Gholam A. | Predictors for patients at risk for glaucoma from steroid therapy |
EP1755616B1 (en) * | 2004-04-08 | 2013-08-14 | Advanced Ocular Systems Limited | Treatment of exudative retinopathy with mineralcorticoids |
US20050232876A1 (en) * | 2004-04-19 | 2005-10-20 | Robin Lynn Minga | Skin care compositions |
EP1740168A2 (en) * | 2004-04-21 | 2007-01-10 | Advanced Ocular Systems Limited | Antiprostaglandins for the treatment of ocular pathologies |
WO2006002067A1 (en) * | 2004-06-15 | 2006-01-05 | Milos Chvapil | Composition and method using local application of lipophilic lathyrogens in sustained release formulations |
US7655682B2 (en) * | 2004-07-02 | 2010-02-02 | Medicis Pharmaceutical Corporation | Triple anti-irritant composition |
US7479289B2 (en) * | 2004-07-02 | 2009-01-20 | Medicis Pharmaceutical Corporation | Stable cleanser compositions containing sulfur |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
DK1809329T3 (en) * | 2004-09-17 | 2012-04-02 | Durect Corp | CONTINUOUS LOCAL ANAESTIC COMPOSITION CONTAINING SAIB |
US20210299056A9 (en) | 2004-10-25 | 2021-09-30 | Varian Medical Systems, Inc. | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
AU2005298344B2 (en) | 2004-10-25 | 2011-02-10 | Varian Medical Systems, Inc. | Loadable polyphosphazene-comprising particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US9107850B2 (en) | 2004-10-25 | 2015-08-18 | Celonova Biosciences, Inc. | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US9114162B2 (en) | 2004-10-25 | 2015-08-25 | Celonova Biosciences, Inc. | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same |
US20060122152A1 (en) * | 2004-12-03 | 2006-06-08 | Peyman Gholam A | Heparin for the treatment of ocular pathologies |
US20080254086A1 (en) * | 2004-12-23 | 2008-10-16 | Brown James E | Controlled Release Compositions |
US20060142234A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
WO2007011880A2 (en) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
US20070014760A1 (en) * | 2005-07-18 | 2007-01-18 | Peyman Gholam A | Enhanced recovery following ocular surgery |
US20070027105A1 (en) * | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
US7456251B2 (en) * | 2006-02-02 | 2008-11-25 | Trimeris, Inc. | HIV fusion inhibitor peptides with improved biological properties |
ZA200807571B (en) | 2006-03-01 | 2009-08-26 | Ethypharm Sa | Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion |
EP1854477B9 (en) | 2006-03-16 | 2018-03-14 | Dyax Corp. | Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders. |
US7458953B2 (en) * | 2006-06-20 | 2008-12-02 | Gholam A. Peyman | Ocular drainage device |
WO2008005371A2 (en) * | 2006-06-29 | 2008-01-10 | Medtronic, Inc. | Poly(orthoester) polymers, and methods of making and using same |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
DK2046382T3 (en) * | 2006-07-10 | 2016-12-12 | Esbatech Alcon Biomed Res Unit | scFv Antibodies which passes through the epithelial and / or endothelial layer |
BRPI0713203A2 (en) * | 2006-07-12 | 2012-04-03 | Controlled Therapeutics Scotland Ltda | insert, methods, packing, recoverable device and insertable device |
GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
PT2117521E (en) * | 2006-11-03 | 2012-09-10 | Durect Corp | Transdermal delivery systems comprising bupivacaine |
FR2910320B1 (en) | 2006-12-21 | 2009-02-13 | Galderma Res & Dev S N C Snc | EMULSION COMPRISING AT LEAST ONE RETINOID AND BENZOLE PEROXIDE |
FR2910321B1 (en) | 2006-12-21 | 2009-07-10 | Galderma Res & Dev S N C Snc | CREAM GEL COMPRISING AT LEAST ONE RETINOID AND BENZOLE PEROXIDE |
US20090022727A1 (en) | 2007-01-26 | 2009-01-22 | Alza Corp. | Injectable, nonaqueous suspension with high concentration of therapeutic agent |
JP2010523564A (en) * | 2007-04-03 | 2010-07-15 | トリメリス,インコーポレーテッド | Novel formulations for delivery of antiviral peptide therapeutics |
HUE030789T2 (en) * | 2007-05-18 | 2017-06-28 | Durect Corp | Improved depot formulations |
NZ581862A (en) | 2007-05-25 | 2012-06-29 | Tolmar Therapeutics Inc | Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient |
JP2010540528A (en) * | 2007-09-25 | 2010-12-24 | トリメリス,インコーポレーテッド | Novel synthesis of therapeutic antiviral peptides |
US9090737B2 (en) * | 2007-11-13 | 2015-07-28 | Surmodics, Inc. | Viscous terpolymers as drug delivery platform |
JP2011506319A (en) | 2007-12-06 | 2011-03-03 | デュレクト コーポレーション | Useful methods for the treatment of pain, joint inflammation symptoms, or inflammation associated with chronic diseases |
AU2013202707C1 (en) * | 2007-12-06 | 2015-07-30 | Durect Corporation | Oral pharmaceutical dosage forms |
US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
CA2714506C (en) * | 2008-02-08 | 2016-06-07 | Qps Llc | Composition for sustained release delivery of proteins or peptides |
CN102131483A (en) | 2008-02-08 | 2011-07-20 | 昌达生物科技公司 | Non-polymeric compositions for controllable drug delivery |
GB0804619D0 (en) * | 2008-03-12 | 2008-04-16 | Norbrook Lab Ltd | A topical ectoparasiticide composition |
US20090263456A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Methods and Compositions for Reducing Preventing and Treating Adhesives |
US8475823B2 (en) * | 2008-04-18 | 2013-07-02 | Medtronic, Inc. | Baclofen formulation in a polyorthoester carrier |
US8956642B2 (en) * | 2008-04-18 | 2015-02-17 | Medtronic, Inc. | Bupivacaine formulation in a polyorthoester carrier |
US20110201869A1 (en) * | 2008-05-07 | 2011-08-18 | Obj Limited | Method and apparatus for enhanced transdermal diffusion |
US9554826B2 (en) | 2008-10-03 | 2017-01-31 | Femasys, Inc. | Contrast agent injection system for sonographic imaging |
US10070888B2 (en) | 2008-10-03 | 2018-09-11 | Femasys, Inc. | Methods and devices for sonographic imaging |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
US8822546B2 (en) * | 2008-12-01 | 2014-09-02 | Medtronic, Inc. | Flowable pharmaceutical depot |
WO2010077732A2 (en) * | 2008-12-09 | 2010-07-08 | Aether Medical Llc | Implantable analgesic |
US9480643B2 (en) | 2008-12-23 | 2016-11-01 | Surmodics Pharmaceuticals, Inc. | Implantable composites and implants comprising same |
US9415197B2 (en) * | 2008-12-23 | 2016-08-16 | Surmodics, Inc. | Implantable suction cup composites and implants comprising same |
US8974808B2 (en) * | 2008-12-23 | 2015-03-10 | Surmodics, Inc. | Elastic implantable composites and implants comprising same |
US8951546B2 (en) * | 2008-12-23 | 2015-02-10 | Surmodics Pharmaceuticals, Inc. | Flexible implantable composites and implants comprising same |
US20100168807A1 (en) * | 2008-12-23 | 2010-07-01 | Burton Kevin W | Bioactive terpolymer compositions and methods of making and using same |
US20120207770A1 (en) | 2009-10-14 | 2012-08-16 | Nanyang Technological University | Antiproliferative agent |
JP5809251B2 (en) | 2010-05-25 | 2015-11-10 | インターナショナル・サイエンティフィック・プロプライエタリー・リミテッド | Delivery of oral care products |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
EP2582424A4 (en) | 2010-06-17 | 2014-08-06 | Internat Scient Pty Ltd | Delivery of skin care products |
US9598532B2 (en) | 2010-08-30 | 2017-03-21 | Surmodics, Inc. | Terpolymers as pressure-sensitive adhesives |
EP2626092B1 (en) * | 2011-04-01 | 2015-08-05 | Zhuhai Ortus Biotechnology Co., Ltd. | Medical absorbable hemostatic material for bone wounds and preparation method therefor |
AU2012321101A1 (en) * | 2011-11-23 | 2013-06-06 | Durect Corporation | Radiation-sterilized biodegradable drug delivery compositions |
BR112014028600B1 (en) | 2012-05-18 | 2022-11-22 | Genentech, Inc | SUSPENSION FORMULATIONS COMPRISING HIGH CONCENTRATION MONOCLONAL ANTIBODY, ITS METHOD OF PREPARATION, ITS USE AND DEVICE FOR SUBCUTANEOUS ADMINISTRATION, AND METHOD FOR PRODUCING AN ARTICLE OF MANUFACTURING |
US10220093B2 (en) | 2013-02-28 | 2019-03-05 | Mira Pharma Corporation | Long-acting semi-solid lipid formulations |
AU2014223993B2 (en) | 2013-02-28 | 2016-09-08 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid formulations and its compostions |
US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
JP2016512523A (en) | 2013-03-11 | 2016-04-28 | デュレクト コーポレーション | Controlled release composition for injection comprising a highly viscous liquid carrier |
CA2905131A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
CN111956598A (en) | 2013-03-15 | 2020-11-20 | 赫伦治疗有限公司 | Composition of polyorthoester and aprotic solvent |
AU2014233462A1 (en) | 2013-03-15 | 2015-10-01 | Durect Corporation | Compositions with thixotropy and enhanced dissolution reproducibility and stability |
US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
WO2015123734A1 (en) * | 2014-02-21 | 2015-08-27 | The University Of Sydney | Liquid carrier materials |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
EP3154552B1 (en) | 2014-06-11 | 2021-03-24 | International Scientific Pty Ltd | Device and method to treat or prevent joint degeneration |
WO2016079331A1 (en) * | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for enhancing the effect of radiotherapy |
CN115501172A (en) * | 2014-11-21 | 2022-12-23 | 丹麦技术大学 | Gel formulations for topical drug delivery |
US11058780B2 (en) * | 2016-05-20 | 2021-07-13 | Technical University Of Denmark | Palpable marker composition |
US20200197315A1 (en) | 2016-07-06 | 2020-06-25 | Durect Corporation | Oral dosage form with drug composition, barrier layer and drug layer |
US11752099B2 (en) * | 2017-03-27 | 2023-09-12 | W. L. Gore & Associates, Inc. | Injectable and biodegradable polymer formulations for controlled release of bioactive agents |
SG11201909478UA (en) | 2017-04-24 | 2019-11-28 | Cocrystal Pharma Inc | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
AU2018283372A1 (en) | 2017-06-16 | 2020-02-06 | Avery Therapeutics, Inc. | Three dimensional tissue compositions and methods of use |
US10561606B2 (en) | 2017-12-06 | 2020-02-18 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid gel formulations |
US11426418B2 (en) | 2017-12-06 | 2022-08-30 | Mira Pharma Corporation | Injectable long-acting semi-solid gel formulations |
CN112638477B (en) | 2018-07-27 | 2024-01-26 | 共晶制药公司 | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication |
EP3849978B1 (en) | 2018-09-10 | 2022-11-02 | Cocrystal Pharma, Inc. | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication |
PT3866778T (en) | 2018-10-17 | 2023-02-28 | Cocrystal Pharma Inc | Combinations of inhibitors of influenza virus replication |
WO2020112716A1 (en) | 2018-11-26 | 2020-06-04 | Cocrystal Pharma, Inc. | Inhibitors of influenza virus replication |
CA3143104A1 (en) | 2019-06-12 | 2020-12-17 | Technical University Of Denmark | Dissacharide formulations for controlled drug release |
KR20220140711A (en) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | Reduced Impurity Sustained Release Drug Delivery Systems and Related Methods |
US20230151034A1 (en) | 2020-03-17 | 2023-05-18 | Cocrystal Pharma, Inc. | Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication |
CA3179697A1 (en) | 2020-04-10 | 2021-10-14 | Cocrystal Pharma, Inc. | Inhibitors of norovirus and coronavirus replication |
WO2023014758A1 (en) | 2021-08-03 | 2023-02-09 | Cocrystal Pharma, Inc. | Inhibitors for coronaviruses |
EP4282435A1 (en) | 2022-05-23 | 2023-11-29 | Danmarks Tekniske Universitet | Formulations of active pharmaceutical ingredients and excipients in icells via hydrophobic ion pairing |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2931802A (en) | 1958-04-30 | 1960-04-05 | Eastman Kodak Co | Mixed esters of glucose and sucrose |
GB1088992A (en) | 1963-09-19 | 1967-10-25 | Squibb & Sons Inc | Protective dressings |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US3743398A (en) | 1971-03-22 | 1973-07-03 | Eastman Kodak Co | Motion picture projector |
NO139560C (en) | 1972-04-29 | 1979-04-04 | Takeda Chemical Industries Ltd | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY EFFECTIVE NONAPEPTIDAMIDE DERIVATIVES |
NL7414241A (en) | 1973-11-01 | 1975-05-06 | Wellcome Found | PROCESS FOR THE PREPARATION OF PEPTIDES AND OF MEDICINAL PRODUCTS CONTAINING THESE PEPTIDES. |
DE2438352A1 (en) | 1974-08-09 | 1976-02-26 | Hoechst Ag | PEPTIDE CYCLOPROPYLAMIDE WITH LH-RH / FSHRH EFFECT |
DE2438350C3 (en) | 1974-08-09 | 1979-06-13 | Hoechst Ag, 6000 Frankfurt | Peptides with a strong LH-RH / FSH-RH action, process for their production and pharmaceutical preparations containing them |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
JPS55154991A (en) * | 1979-05-23 | 1980-12-02 | Hisamitsu Pharmaceut Co Inc | Beta-d-fructopyranoside derivative |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
DE3716302C2 (en) * | 1987-05-15 | 1996-02-01 | Henkel Kgaa | Improved absorbable bone waxes and their use |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4622219A (en) | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
IT1198449B (en) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID |
US5391381A (en) | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
JPH0296516A (en) | 1988-09-29 | 1990-04-09 | Dainippon Pharmaceut Co Ltd | Granule and production thereof |
US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5324520A (en) | 1988-12-19 | 1994-06-28 | Vipont Pharmaceutical, Inc. | Intragingival delivery systems for treatment of periodontal disease |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
IT1240643B (en) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN |
US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
WO1992017900A1 (en) | 1991-04-03 | 1992-10-15 | Eastman Kodak Company | HIGH DURABILITY MASK FOR DRY ETCHING OF GaAs |
JP3313124B2 (en) | 1991-07-31 | 2002-08-12 | 森下仁丹株式会社 | SEAMLESS CAPSULES CONTAINING A HYDROPHILIC SUBSTANCE AND PROCESS FOR PRODUCING THE SAME |
US5487898A (en) | 1991-08-26 | 1996-01-30 | Abbott Laboratories | Compositions and method for the sublingual or buccal administration therapeutic agents |
YU87892A (en) | 1991-10-01 | 1995-12-04 | Eli Lilly And Company Lilly Corporate Center | INJECTIBLE LONG TERM RELEASE FORMULATIONS AND PROCEDURES FOR THEIR OBTAINING AND USE |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
JP3313113B2 (en) | 1991-10-21 | 2002-08-12 | ペプテック リミテッド | Biocompatible implants for controlling ovulation in mares |
ATE236655T1 (en) * | 1993-01-06 | 2003-04-15 | Kinerton Ltd | IONIC MOLECULAR CONJUGATES OF BIODEGRADABLE POLYESTERS AND BIOACTIVE POLYPEPTIDES |
US5340572A (en) | 1993-02-08 | 1994-08-23 | Insite Vision Incorporated | Alkaline ophthalmic suspensions |
ES2122261T3 (en) | 1993-03-17 | 1998-12-16 | Minnesota Mining & Mfg | AEROSOL FORMULATION CONTAINING A DISPERSION ADJUVANT DERIVED FROM AN ESTER, AMIDA OR MERCAPTOESTER. |
JPH08507792A (en) | 1993-03-17 | 1996-08-20 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Aerosol formulations containing dispersion aids derived from diol-diacids |
DE4322826A1 (en) * | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmaceutical preparation |
JP3257750B2 (en) * | 1993-07-20 | 2002-02-18 | エチコン・インコーポレーテツド | Liquid copolymer of ε-caprolactone and lactide |
TW282403B (en) | 1993-08-26 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
JPH07115901A (en) | 1993-10-28 | 1995-05-09 | Fuji Bibaretsuji:Kk | Emulsified composition and drink rich in docosahexaenoic acid |
AU681231B2 (en) | 1993-12-29 | 1997-08-21 | Intarcia Therapeutics, Inc. | Methods and compositions for the treatment of a host with a cellular proliferative disease |
JP4259610B2 (en) | 1994-04-08 | 2009-04-30 | キューエルティー・ユーエスエイ・インコーポレーテッド | Liquid delivery composition |
US5599852A (en) * | 1994-10-18 | 1997-02-04 | Ethicon, Inc. | Injectable microdispersions for soft tissue repair and augmentation |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
DE69634277T2 (en) | 1995-06-07 | 2006-01-05 | Southern Biosystems, Inc., Birmingham | CONTROLLED FEEDING SYSTEM WITH A LIQUID OF HIGH VISCOSITY |
US6413536B1 (en) * | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US5968542A (en) * | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
JPH10115901A (en) | 1996-10-09 | 1998-05-06 | Noritsu Koki Co Ltd | Photographic developing processor |
US6331311B1 (en) | 1996-12-20 | 2001-12-18 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
DE19714765A1 (en) * | 1997-04-10 | 1998-10-15 | Merck Patent Gmbh | Use of low molecular weight, oligomeric esters of alpha-hydroxy acids and / or aromatic o-hydroxy acids in cosmetic formulations |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6051558A (en) | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
DE19858891A1 (en) * | 1998-12-19 | 2000-06-21 | Merck Patent Gmbh | Improved bone seals |
AU5025300A (en) | 1999-06-18 | 2001-01-09 | Southern Biosystems, Inc. | Compositions for controlled release of the hormone gnrh and its analogs |
-
1999
- 1999-08-27 US US09/385,107 patent/US6413536B1/en not_active Expired - Lifetime
-
2000
- 2000-08-24 AT AT00961358T patent/ATE307611T1/en not_active IP Right Cessation
- 2000-08-24 CA CA002382540A patent/CA2382540C/en not_active Expired - Fee Related
- 2000-08-24 WO PCT/US2000/023270 patent/WO2001015734A2/en active IP Right Grant
- 2000-08-24 AU AU73319/00A patent/AU7331900A/en not_active Abandoned
- 2000-08-24 EP EP00961358A patent/EP1212092B1/en not_active Expired - Lifetime
- 2000-08-24 ES ES00961358T patent/ES2254219T3/en not_active Expired - Lifetime
- 2000-08-24 DE DE60023520T patent/DE60023520T2/en not_active Expired - Lifetime
- 2000-08-24 JP JP2001520145A patent/JP4276807B2/en not_active Expired - Lifetime
- 2000-10-26 US US09/699,002 patent/US7053209B1/en not_active Expired - Fee Related
-
2005
- 2005-09-01 AU AU2005205766A patent/AU2005205766A1/en not_active Abandoned
-
2006
- 2006-05-24 US US11/440,642 patent/US20060210599A1/en not_active Abandoned
-
2009
- 2009-01-08 JP JP2009002735A patent/JP2009143935A/en active Pending
- 2009-04-03 AU AU2009201321A patent/AU2009201321A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7053209B1 (en) | 2006-05-30 |
WO2001015734A2 (en) | 2001-03-08 |
AU7331900A (en) | 2001-03-26 |
DE60023520T2 (en) | 2006-07-27 |
AU2005205766A1 (en) | 2005-09-29 |
EP1212092B1 (en) | 2005-10-26 |
EP1212092A2 (en) | 2002-06-12 |
AU2009201321A1 (en) | 2009-04-23 |
ATE307611T1 (en) | 2005-11-15 |
US6413536B1 (en) | 2002-07-02 |
WO2001015734A3 (en) | 2001-09-13 |
JP4276807B2 (en) | 2009-06-10 |
US20060210599A1 (en) | 2006-09-21 |
DE60023520D1 (en) | 2005-12-01 |
ES2254219T3 (en) | 2006-06-16 |
CA2382540C (en) | 2009-06-16 |
JP2009143935A (en) | 2009-07-02 |
JP2003508449A (en) | 2003-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2382540A1 (en) | High viscosity liquid composition for the delivery of substances | |
WO2004052336A3 (en) | High viscosity liquid controlled delivery system and medical or surgical device | |
MY118835A (en) | Sustained release compositions and the process for their preparation | |
EP2289549A3 (en) | Immunoconjugates for treating cancer | |
CA2462606A1 (en) | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer | |
GEP20043375B (en) | APRIL-Receptor (BCMA) and Use Thereof | |
CA2270286A1 (en) | Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device | |
WO2003015849A3 (en) | Delivering material to a patient | |
WO2002000171A3 (en) | Composition for delivery of hematopoietic growth factor | |
CA2394672A1 (en) | Biodegradable polymer composition | |
WO2004032862A3 (en) | Cyclodextrin-based materials, compositions and uses related thereto | |
CA2338358A1 (en) | Compounds and compositions for delivering active agents | |
WO2005051456A3 (en) | Composition and apparatus for transdermal delivery | |
ATE350013T1 (en) | NANOPARTICLE COMPOSITIONS CONTAINING INSULIN | |
FI962154A (en) | Composition for the in vivo preparation of therapeutic products | |
WO2006130455A3 (en) | Bioresorbable polymer matrices and methods of making and using the same | |
GEP20053427B (en) | Pharmaceutical Compositions Providing Enhanced Drug Concentrations | |
WO2001032596A8 (en) | Phenoxy carboxylic acid compounds and compositions for delivering active agents | |
WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
CA2361402A1 (en) | Bis-sulfonamides | |
ATE311373T1 (en) | OXADIAZOLE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS | |
EP2308479A3 (en) | Compounds and compositions for delivering active agents | |
EP1608408A4 (en) | Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same | |
CA2359491A1 (en) | Mixture of plant treatment compositions with waxes, their preparation, and their use | |
EP1080724A4 (en) | Mtp activity-lowering compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140826 |